Pharma & Biotech VC & Investment News
Biotechnology
Danish life sciences investor Novo Holdings is continuing the spread of its cash pile, this time as co-leader of a $181.4 million Series D financing in Alentis Therapeutics. 12 November 2024
Today's issue
Refine Search
Generics
Netherlands-incorporated Mylan’s (Nasdaq: MYL) shares were down 7.9% at $31.79 in pre-market trading, after the company released second-quarter 2017 financial results which missed expectations, and reduced its full-year guidance. 9 August 2017
Pharmaceutical
Strong second quarter results were posted by Danish CNS specialist Lundbeck today, with revenue of 4.3 billion Danish kroner ($663 million), a touch higher than the Financial Times’ consensus forecast of 4.17 billion kroner. 9 August 2017
Pharmaceutical
For the second quarter in a row, the results of Danish diabetes giant Novo Nordisk have sent the company’s share price soaring. 9 August 2017
Pharmaceutical
Beleaguered Canadian firm Valeant Pharmaceuticals International reported a 7.8 % decline in revenues to $2.23 billion in the second quarter of 2017, hurt by lower volume and pricing of its generic and neurology products. 8 August 2017
Pharmaceutical
There were again a number of important financial results reports in the past week, with three – Pfizer, Shire and Teva Pharmaceutical Industries – attracting most external comments. Clovis Oncology’s deal with Bristol-Myers Squibb on its cancer drug Rubraca had a negative impact on the former’s, share price and - for a change in recent times – there was good news for AstraZeneca with regard to its cancer drug Imfinzi. 7 August 2017
Biotechnology
US biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN) today announced financial results for the second quarter of 2017, showing that total revenue rose 21% to $1.47 billion from $1.21 billion. 3 August 2017
Pharmaceutical
Allergan has slipped by 1.2% in the opening moments of Thursday’s trading to $247.30 after announcing its 2nd-qtr 2017 results. 3 August 2017
article
Boehringer Ingelheim has delivered positive results for the first half of 2017. Net sales increased by 24% to 9.2 billion euros ($10.86 billion) on the same period in the previous year after adjustment for currency effects (+27% in euro terms). 2 August 2017
Pharmaceutical
Pfizer, the world’s biggest pharma company, has beaten earnings expectations but fallen short of analysts’ sales predictions in its latest quarterly results. 1 August 2017
Biotechnology
Australian biopharmaceutical company Neuren Pharmaceuticals has landed a A$10 million ($8 million) investment from UK-based Lanstead Investors, and a further A$1.5 million from other investors. 1 August 2017
Biotechnology
UK biotech firm Redx Pharma has agreed to sell its technology and drug discovery program to Loxo Oncology for $40 million, to pay off around £3.5 million ($4.6 million) debt to a local government body. 31 July 2017
Pharmaceutical
In terms of volume, last week’s news was dominated by dozens of second-quarter earnings reports from pharma and biotech companies. However, overshadowing these was the big blow to AstraZeneca, which on Thursday reported that the much anticipate Mystic trial of its new cancer drug candidate Imfinzi had failed in its goals, which wiped about £10 billion off the company’s market capitalization. Other headline hitting stories included Celgene’s results, Eli Lilly’s collaboration with Nektar Therapeutics, and Samsung Bioepis and Merck & Co’s approval of a Remicade biosimilar Renflexis. 30 July 2017
Pharmaceutical
Merck & Co beat analyst predictions with its second quarter earnings, with soaring sales for the immuno-oncology drug Keytruda (pembrolizumab) proving crucial. 28 July 2017
Biotechnology
US drugmaker AbbVie today reported that second-quarter 2017 net earnings rose to $1.92 billion, or earnings per share of $1.19 per share in the second quarter, a rise of 12.7% year-on-year. 28 July 2017
Pharmaceutical
Italian drugmaker Recordati has posted a strong set of financial results for the first half of 2017, underlining the continued growth of the group, with revenues and profitability increasing significantly. 28 July 2017
Pharmaceutical
So far as investors are concerned, news from across the Atlantic has overshadowed a set of quarterly financial results from US pharma major Bristol-Myers Squibb that met or beat analyst expectations. 27 July 2017
Biotechnology
US biotech major Celgene saw its shares rise 1.6% in pre-market trading, but were down nearly 1% at $136.40 late morning, despite reporting second quarter 2017 sales and earnings that beat consensus expectations. 27 July 2017
Pharmaceutical
AstraZeneca suffered a fierce blow on Thursday with the announcement of the failure of its high-profile lung cancer trial Mystic to meet a primary endpoint in initial results, and its second quarter financial results, presented on the same day, did not offer much encouragement for the future either. 27 July 2017
Pharmaceutical
French specialty pharma group Ipsen (Euronext: IPN) today announced financial results for the first half of 2017, reporting strong operating performance. 27 July 2017
Pharmaceutical
Reduced growth forecasts at German life sciences group Bayer hit the company’s stocks hard on Wednesday morning, with its share price sliding by 3% to 108.65 euros in three hours after the announcement of the latest quarterly financials. 27 July 2017
Biotechnology
California-based venture capital firm Versant Ventures yesterday announced the launch of Pep2Tango Therapeutics, a start-up focused on innovative, next-generation weight loss therapies. Proceeds from the significant, undisclosed round will support development of the company’s novel unimolecular tetra-receptor agonist peptides to treat obesity and related conditions. 22 November 2024
Biotechnology
Hong Kong-based Sino Biopharm has signed an equity investment and strategic collaboration agreement with LaNova Medicines, advancing its oncology focus. 22 November 2024
Biotechnology
Colorado, USA-based biotech Enveda Biosciences, which is using AI to translate nature into new medicines, has announced an oversubscribed $130 million Series C funding round led by Kinnevik and FPV. 22 November 2024
Biotechnology
San Diego-based Cidara Therapeutics, a biotech using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, has entered into a securities purchase agreement with certain investors to raise up to around $105 million. 21 November 2024
Biotechnology
Aizen Therapeutics, an AI-driven biotech headquartered in San Diego, has officially launched from stealth mode, introducing its drug discovery platform, DaX. 21 November 2024
Biotechnology
San Diego-based Valora Therapeutics, a biotech that boasts of having a novel approach to immunotherapy, has announced the successful closing of a $30 million seed funding round. 21 November 2024
article
The UK government has reappointed BioIndustry Association (BIA) chairman Daniel Mahony as its Life Sciences Investment Envoy. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Biotechnology
A pair of industry veterans have teamed up to create Jupiter Bioventures, a San Francisco-based biotech venture foundry promised to build bold, science-driven therapeutics companies. 20 November 2024
Biotechnology
Aclaris Therapeutics has announced an exclusive licensing agreement with Biosion for broad rights to two new antibodies. 19 November 2024
Biotechnology
Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates. 19 November 2024
Pharmaceutical
In yet another sign of the mounting interest in radiopharmaceuticals, Tongrui Biopharma, a Chinese innovator in this area, has announced the completion of a $100 million series A+ financing round. 18 November 2024
Biotechnology
Shanghai-based biopharma Zai Lab has announced the pricing of its underwritten public offering at $25.50 per share, aiming to raise around $200 million. 15 November 2024
Pharmaceutical
New York-based Metsera, a biopharma developing medicines for obesity and metabolic diseases, has closed a $215 million Series B financing to further advance its portfolio of clinical-stage, nutrient-stimulated hormone (NuSH) analog peptides. 14 November 2024
Pharmaceutical
Life science investor Syncona has announced the launch of its newest portfolio company, Slingshot Therapeutics, through the Syncona Accelerator initiative. 14 November 2024
Biotechnology
Danish life sciences investor Novo Holdings is continuing the spread of its cash pile, this time as co-leader of a $181.4 million Series D financing in Alentis Therapeutics. 12 November 2024
Biotechnology
Trace Neuroscience, a newly launched biopharma based in San Francisco, aims to advance treatments for neurodegenerative diseases, starting with amyotrophic lateral sclerosis (ALS). 12 November 2024
Biotechnology
Geron Corporation, a biopharma company focused on telomerase inhibition therapies, has announced a $375 million financing agreement aimed at supporting the commercial rollout of Rytelo (imetelstat). 11 November 2024
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 11 November 2024
Biotechnology
US biotech venture fund Aditum Bio and China’s Leads Biolabs today announced the formation of Oblenio Bio, marking the thirteenth company launched by Aditum. 7 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze